Surrozen (SRZN) Change in Account Payables (2020 - 2026)
Surrozen (SRZN) posted quarterly Change in Account Payables of $161000.0 for Q1 2026, up 4125.0% year-over-year from $3810.7 in Q1 2025, and up 278.89% quarter-over-quarter from -$90000.0 in Q4 2025.
Powered by 
Analysis
Surrozen (SRZN) Change in Account Payables (2020 - 2026) Analysis & Trends
Surrozen's Change in Account Payables history runs 7 years deep, the most recent figure standing at $161000.0 for Q1 2026.
- In Q1 2026, Change in Account Payables rose 4125.0% year-over-year to $161000.0; the TTM figure through Mar 2026 stood at $307000.0 (up 89.51% YoY), while the FY2025 annual figure was $142000.0, up 162.28% from the prior year.
- Change in Account Payables for Q1 2026 stood at $161000.0, up from -$90000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $327000.0 in Q4 2022, with the low at -$1.8 million in Q1 2022.
- The 5-year median for Change in Account Payables is $21000.0 (2024), against an average of -$123294.1.
- The sharpest annual moves came in 2025 and 2026: Change in Account Payables tumbled 528.57% in 2025, then soared 4125.0% in 2026.
- Surrozen's Change in Account Payables stood at $327000.0 in 2022, then declined by 27.22% to $238000.0 in 2023, then sank by 91.18% to $21000.0 in 2024, then sank by 528.57% to -$90000.0 in 2025, then soared by 278.89% to $161000.0 in 2026.
- Business Quant data shows SRZN's Change in Account Payables at $161000.0 in Q1 2026, -$90000.0 in Q4 2025, and $184000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | - |
| 10 | Surrozen | 259.68 Mn | 259.68 Mn | - | 184,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 184,000.00 |
| Mar 31, 2026 | 161,000.00 |
| Dec 31, 2025 | -90,000.00 |
| Sep 30, 2025 | 184,000.00 |
| Jun 30, 2025 | 52,000.00 |
| Mar 31, 2025 | -4,000.00 |
| Dec 31, 2024 | 21,000.00 |
| Sep 30, 2024 | 103,000.00 |
| Jun 30, 2024 | 42,000.00 |
| Mar 31, 2024 | -394,000.00 |
| Dec 31, 2023 | 238,000.00 |
| Sep 30, 2023 | 101,000.00 |
| Jun 30, 2023 | 15,000.00 |
| Mar 31, 2023 | -487,000.00 |
| Dec 31, 2022 | 327,000.00 |
| Sep 30, 2022 | -87,000.00 |
| Jun 30, 2022 | -523,000.00 |
| Mar 31, 2022 | -1.76 Mn |
| Dec 31, 2021 | 728,000.00 |
| Sep 30, 2021 | 766,000.00 |